The expanding incretin universe: from basic biology to clinical translation

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1× · see citing works

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203 · see citing works

Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1

Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · see citing works

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1× · see citing works

A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis

Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · see citing works

Glucagon-like peptide-1 7–36: a physiological incretin in man

Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928 · see citing works

The Immunological Genome Project: networks of gene expression in immune cells

The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864 · see citing works

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651 · see citing works

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials

Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 8× · see citing works

Single-Cell Transcriptome Profiling of Human Pancreatic Islets in Health and Type 2 Diabetes

Segerstolpe, Å., Palasantza, A., Eliasson, P., Andersson, E.-M., Andréasson, A.-C., Sun, X., Picelli, S., Sabirsh, A., Clausen, M., Bjursell, M. K., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.08.020 · Cited by 1,550 · see citing works

Reduced incretin effect in Type 2 (non-insulin dependent) diabetes

Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · see citing works

The mechanism of pancreatic secretion

Bayliss, W. M., & Starling, E. H. (1902) · The Journal of Physiology · doi:10.1113/jphysiol.1902.sp000920 · Cited by 1,274 · see citing works

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients

Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · see citing works

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · see citing works

Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells

Ellingsgaard, H., Hauselmann, I., Schuler, B., Habib, A. M., Baggio, L. L., Meier, D. T., Eppler, E., Bouzakri, K., Wueest, S., Muller, Y. D., et al. (2011) · Nature Medicine · doi:10.1038/nm.2513 · Cited by 922 · see citing works

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line.

Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · see citing works

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · see citing works

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.

Mojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882 · see citing works

Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses

NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874 · see citing works

STIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. ¹

Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860 · see citing works

Plasma Insulin Response to Oral and Intravenous Glucose Administration1

ELRICK, H., STIMMLER, L., HLAD, C. J., & ARAI, Y. (1964) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-24-10-1076 · Cited by 857 · see citing works

Glucagon-like peptide-1 receptor is involved in learning and neuroprotection

During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · see citing works

Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial

Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 1× · see citing works

Glucose intolerance but normal satiety in mice with a null mutation in the glucagon–like peptide 1 receptor gene

Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · see citing works

New Interpretation of Oral Glucose Tolerance

Mcintyre, N., Holdsworth, C. D., & Turner, D. S. (1964) · The Lancet · doi:10.1016/s0140-6736(64)90011-x · Cited by 738 · see citing works

The incretin concept today

Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731 · see citing works

Semaglutide lowers body weight in rodents via distributed neural pathways.

Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · see citing works

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · see citing works

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · see citing works

Na+-<scp>d</scp>-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose Absorption and Glucose-Dependent Incretin Secretion

Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687 · see citing works

Enteroendocrine Cells: Chemosensors in the Intestinal Epithelium

Gribble, F. M., & Reimann, F. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105439 · Cited by 683 · see citing works

The Cardiovascular Biology of Glucagon-like Peptide-1

Drucker, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.06.009 · Cited by 665 · see citing works

Hamster preproglucagon contains the sequence of glucagon and two related peptides

Bell, G. I., Santerre, R. F., & Mullenbach, G. T. (1983) · Nature · doi:10.1038/302716a0 · Cited by 649 · see citing works

Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut

Holst, J. J., Ørskov, C., Nielsen, O. V., & Schwartz, T. W. (1987) · FEBS Letters · doi:10.1016/0014-5793(87)81430-8 · Cited by 615 · see citing works

Exon duplication and divergence in the human preproglucagon gene

Bell, G. I., Sanchez-Pescador, R., Laybourn, P. J., & Najarian, R. C. (1983) · Nature · doi:10.1038/304368a0 · Cited by 593 · see citing works

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial

Jorsal, A., Kistorp, C., Holmager, P., Tougaard, R. S., Nielsen, R., Hänselmann, A., Nilsson, B., Møller, J. E., Hjort, J., Rasmussen, J., et al. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.657 · Cited by 592 · see citing works

<i>Gpr40</i> Is Expressed in Enteroendocrine Cells and Mediates Free Fatty Acid Stimulation of Incretin Secretion

Edfalk, S., Steneberg, P., & Edlund, H. (2008) · Diabetes · doi:10.2337/db08-0307 · Cited by 587 · see citing works

GLP-1R Agonist Liraglutide Activates Cytoprotective Pathways and Improves Outcomes After Experimental Myocardial Infarction in Mice

Noyan-Ashraf, M. H., Momen, M. A., Ban, K., Sadi, A.-M., Zhou, Y.-Q., Riazi, A. M., Baggio, L. L., Henkelman, R. M., Husain, M., & Drucker, D. J. (2009) · Diabetes · doi:10.2337/db08-1193 · Cited by 575 · see citing works

Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1× · see citing works

Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial

Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology &amp; Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · see citing works

Exenatide and the treatment of patients with Parkinson's disease

Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529 · see citing works

Promotion of Insulin Secretion by Glucagon

Samols, E., Marri, G., & Marks, V. (1965) · The Lancet · doi:10.1016/s0140-6736(65)90761-0 · Cited by 521 · see citing works

Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients

T., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518 · see citing works

GLP-1 receptor activation and epac2 link atrial natriuretic peptide secretion to control of blood pressure

Kim, M., Platt, M. J., Shibasaki, T., Quaggin, S. E., Backx, P. H., Seino, S., Simpson, J. A., & Drucker, D. J. (2013) · Nature Medicine · doi:10.1038/nm.3128 · Cited by 514 · see citing works

GLP-1 physiology informs the pharmacotherapy of obesity

Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101351 · Cited by 510 · see citing works

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Rakipovski, G., Rolin, B., Nøhr, J., Klewe, I., Frederiksen, K. S., Augustin, R., Hecksher-Sørensen, J., Ingvorsen, C., Polex-Wolf, J., & Knudsen, L. B. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2018.09.004 · Cited by 509 · see citing works

GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting

Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477 · see citing works

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

Vilsbøll, T., Krarup, T., Madsbad, S., & Holst, J. J. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00111-3 · Cited by 430 · see citing works

Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes

Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414 · see citing works

Effect of Truncated Glucagon-Like Peptide-1 [Proglucagon-(78–107) amide] on Endocrine Secretion from Pig Pancreas, Antrum, and Nonantral Stomach

Ørskov, C., Holst, J. J., & Nielsen, O. V. (1988) · Endocrinology · doi:10.1210/endo-123-4-2009 · Cited by 400 · see citing works

Neuronal GLP1R mediates liraglutide’s anorectic but not glucose-lowering effect

Sisley, S. R., Gutiérrez‐Aguilar, R., Scott, M. M., D’Alessio, D. A., Sandoval, D. A., & Seeley, R. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72434 · Cited by 394 · see citing works

Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans

Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J. (2011) · Diabetes · doi:10.2337/db10-0474 · Cited by 392 · see citing works

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

Chu, Z., Carroll, C., Alfonso, J., Gutierrez, V., He, H., Lucman, A., Pedraza, M., Mondala, H., Gao, H., Bagnol, D., et al. (2008) · Endocrinology · doi:10.1210/en.2007-0966 · Cited by 387 · see citing works

GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine

Mortensen, K., Lundby‐Christensen, L., Holst, J. J., & Ørskov, C. (2003) · Regulatory Peptides · doi:10.1016/s0167-0115(03)00125-3 · Cited by 360 · see citing works

Insulin Secretion Depends on Intra-islet Glucagon Signaling

Svendsen, B., Larsen, O., Gabe, M. B. N., Christiansen, C. B., ROSENKILDE, M. M., Drucker, D. J., & Holst, J. J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.018 · Cited by 356 · see citing works

GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE−/− Mice

Panjwani, N., Mulvihill, E. E., Longuet, C., Yusta, B., Campbell, J. E., Brown, T. J., Streutker, C., Holland, D., Cao, X., Baggio, L. L., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1937 · Cited by 346 · see citing works

Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis

Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · see citing works

A Gastric Inhibitory Polypeptide II: The Complete Amino Acid Sequence

Brown, J. C., & Dryburgh, J. R. (1971) · Canadian Journal of Biochemistry · doi:10.1139/o71-122 · Cited by 344 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake

Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324 · see citing works

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling

Zhang, Q., Delessa, C. T., Augustin, R., Bakhti, M., Colldén, G., Drucker, D. J., Feuchtinger, A., Caceres, C. G., Grandl, G., Harger, A., et al. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.01.015 · Cited by 322 · see citing works

GLP-1 response to oral glucose is reduced in prediabetes, screen-detected type 2 diabetes, and obesity and influenced by sex: the ADDITION-PRO study

Færch, K., Torekov, S. S., Vistisen, D., Johansen, N. B., Witte, D. R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. (2015) · Diabetes · doi:10.2337/db14-1751 · Cited by 321 · see citing works

The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes

Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · see citing works

GLP-1 Receptor Expression Within the Human Heart

Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · see citing works

Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial

Cukierman-Yaffe, T., Gerstein, H. C., Colhoun, H. M., Diaz, R., García-Pérez, L.-E., Lakshmanan, M., Bethel, A., Xavier, D., Probstfield, J., Riddle, M. C., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30173-3 · Cited by 300 · see citing works

Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease.

Baggio, L. L., & Drucker, D. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101090 · Cited by 299 · see citing works

Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment

Kopp, K. O., Glotfelty, E. J., Li, Y., & Greig, N. H. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106550 · Cited by 298 · see citing works

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

Lund, P. K., Goodman, R. H., Dee, P. C., & Habener, J. F. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.2.345 · Cited by 295 · see citing works

Glucagon-Like Peptide-1-Responsive Catecholamine Neurons in the Area Postrema Link Peripheral Glucagon-Like Peptide-1 with Central Autonomic Control Sites

Yamamoto, H., Kishi, T., Lee, C. E., Choi, B. J., Fang, H., Hollenberg, A. N., Drucker, D. J., & Elmquist, J. K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02939.2003 · Cited by 294 · see citing works

Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation

McLean, B. A., Wong, C. K., Campbell, J. E., Hodson, D. J., Trapp, S., & Drucker, D. J. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnaa032 · Cited by 289 · see citing works

Exenatide Exerts a Potent Antiinflammatory Effect

Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284 · see citing works

GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R

Yusta, B., Baggio, L. L., Koehler, J., Holland, D., Cao, X., Pinnell, L. J., Johnson-Henry, K. C., Yeung, W., Surette, M. G., Bang, K. W. A., et al. (2015) · Diabetes · doi:10.2337/db14-1577 · Cited by 282 · see citing works

The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice

Hsieh, J., Longuet, C., Baker, C. L., Qin, B., Federico, L. M., Drucker, D. J., & Adeli, K. (2009) · Diabetologia · doi:10.1007/s00125-009-1611-5 · Cited by 276 · see citing works

Central and peripheral GLP-1 systems independently suppress eating

Brierley, D. I., Holt, M. K., Singh, A., de Araujo, A., McDougle, M., Vergara, M., Afaghani, M. H., Lee, S. J., Scott, K., Maske, C., et al. (2021) · Nature Metabolism · doi:10.1038/s42255-021-00344-4 · Cited by 265 · see citing works

A Glucagon-Like Peptide-1 Analog Reverses the Molecular Pathology and Cardiac Dysfunction of a Mouse Model of Obesity

Noyan-Ashraf, M. H., Shikatani, E. A., Schuiki, I., Mukovozov, I., Wu, J., Li, R.-K., Volchuk, A., Robinson, L. A., Billia, F., Drucker, D. J., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.091215 · Cited by 259 · see citing works

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice

Nagashima, M., Watanabe, T., Terasaki, M., Tomoyasu, M., Nohtomi, K., Kim-Kaneyama, J., Miyazaki, A., & Hirano, T. (2011) · Diabetologia · doi:10.1007/s00125-011-2241-2 · Cited by 259 · see citing works

The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review

Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248 · see citing works

Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1

Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244 · see citing works

Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion

Lebrun, L. J., Lenaerts, K., Kiers, D., Pais de Barros, J.-P., Le Guern, N., Plesnik, J., Thomas, C., Bourgeois, T., Dejong, C. H. C., Kox, M., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.008 · Cited by 238 · see citing works

Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models

Killion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · see citing works

Mammalian pancreatic preproglucagon contains three glucagon-related peptides.

Lopez, L. C., Frazier, M. L., Su, C. J., Kumar, A., & Saunders, G. F. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.18.5485 · Cited by 234 · see citing works

Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

Mroz, P. A., Finan, B., Gelfanov, V., Yang, B., Tschöp, M. H., DiMarchi, R. D., & Perez-Tilve, D. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2018.12.001 · Cited by 229 · see citing works

Glucagon-Like Peptide (GLP)-1(9-36)Amide-Mediated Cytoprotection Is Blocked by Exendin(9-39) Yet Does Not Require the Known GLP-1 Receptor

Ban, K., Kim, K.-H., Cho, C.-K., Sauvé, M., Diamandis, E. P., Backx, P. H., Drucker, D. J., & Husain, M. (2010) · Endocrinology · doi:10.1210/en.2009-1197 · Cited by 225 · see citing works

Impaired regulation of the incretin effect in patients with type 2 diabetes

Bagger, J. I., Knop, F. K., Lund, A., Vestergaard, H., Holst, J. J., & Vilsbøll, T. (2011) · The Journal of Clinical Endocrinology &amp; Metabolism · doi:10.1210/jc.2010-2435 · Cited by 219 · see citing works

The primary structure of porcine glicentin (proglucagon)

Thim, L., & Moody, A. J. (1981) · Regulatory Peptides · doi:10.1016/0167-0115(81)90007-0 · Cited by 216 · see citing works

Gut-brain communication by distinct sensory neurons differently controls feeding and glucose metabolism

Borgmann, D., Ciglieri, E., Biglari, N., Brandt, C., Cremer, A. L., Backes, H., Tittgemeyer, M., Wunderlich, F. T., Brüning, J. C., & Fenselau, H. (2021) · Cell Metabolism · doi:10.1016/j.cmet.2021.05.002 · Cited by 213 · see citing works

Complete Sequences of Glucagon-like Peptide-1 from Human and Pig Small Intestine

Ørskov, C., Bersani, M., Johnsen, A. H., Højrup, P., & Holst, J. J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)51561-1 · Cited by 210 · see citing works

Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon

Heinrich, G., Gros, P., & Habener, J. F. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)89859-3 · Cited by 207 · see citing works

GIP receptor agonism attenuates GLP-1 receptor agonist induced nausea and emesis in preclinical models

Borner, T., Geisler, C. E., Fortin, S. M., Cosgrove, R., Alsina-Fernandez, J., Dogra, M., Doebley, S., Sanchez-Navarro, M. J., Leon, R. M., Gaisinsky, J., et al. (2021) · Diabetes · doi:10.2337/db21-0459 · Cited by 202 · see citing works

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes

Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197 · see citing works

Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow

Wettergren, A., Wøjdemann, M., & Holst, J. J. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g984 · Cited by 194 · see citing works

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193 · see citing works

Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery

Svane, M. S., Jørgensen, N. B., Bojsen-Møller, K. N., Dirksen, C., Nielsen, S., Kristiansen, V. B., Toräng, S., Wewer Albrechtsen, N. J., Rehfeld, J. F., Hartmann, B., et al. (2016) · International Journal of Obesity · doi:10.1038/ijo.2016.121 · Cited by 185 · see citing works

The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty

Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C. P., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183 · see citing works

Targeted Ablation of Glucose-dependent Insulinotropic Polypeptide-producing Cells in Transgenic Mice Reduces Obesity and Insulin Resistance Induced by a High Fat Diet

Althage, M. C., Ford, E. L., Wang, S., Tso, P., Polonsky, K. S., & Wice, B. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710466200 · Cited by 180 · see citing works

Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease

Yabut, J. M., & Drucker, D. J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac018 · Cited by 180 · see citing works

Glucagon lowers glycemia when β cells are active

Capozzi, M. E., Wait, J. B., Koech, J., Gordon, A. N., Coch, R. W., Svendsen, B., Finan, B., D’Alessio, D. A., & Campbell, J. E. (2019) · JCI Insight · doi:10.1172/jci.insight.129954 · Cited by 168 · see citing works

Glucagon-like peptide-1 receptor signalling selectively regulates murine lymphocyte proliferation and maintenance of peripheral regulatory T cells

Hadjiyanni, I., Siminovitch, K. A., Danska, J. S., & Drucker, D. J. (2010) · Diabetologia · doi:10.1007/s00125-009-1643-x · Cited by 166 · see citing works

Lipopolysaccharides-Mediated Increase in Glucose-Stimulated Insulin Secretion: Involvement of the GLP-1 Pathway

Nguyen, A. T., Mandard, S., Dray, C., Deckert, V., Valet, P., Besnard, P., Drucker, D. J., Lagrost, L., & Grober, J. (2014) · Diabetes · doi:10.2337/db13-0903 · Cited by 161 · see citing works

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( <scp>GLP</scp> ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <scp>long‐acting GLP</scp> ‐1 receptor agonists

Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143 · see citing works

Gut-Proglucagon-Derived Peptides Are Essential for Regulating Glucose Homeostasis in Mice

Song, Y., Koehler, J. A., Baggio, L. L., Powers, A. C., Sandoval, D. A., & Drucker, D. J. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.08.009 · Cited by 140 · see citing works

Divergent roles for the gut intraepithelial lymphocyte GLP-1R in control of metabolism, microbiota, and T cell-induced inflammation

Wong, C. K., Yusta, B., Koehler, J. A., Baggio, L. L., McLean, B. A., Matthews, D., Seeley, R. J., & Drucker, D. J. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.08.003 · Cited by 138 · see citing works

The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial

Gerstein, H. C., Hart, R., Colhoun, H. M., Diaz, R., Lakshmanan, M., Botros, F. T., Probstfield, J., Riddle, M. C., Rydén, L., Atisso, C. M., et al. (2020) · The Lancet Diabetes &amp; Endocrinology · doi:10.1016/s2213-8587(19)30423-1 · Cited by 137 · see citing works

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Dawed, A. Y., Mari, A., Brown, A. A., McDonald, T. J., Li, L., Wang, S., Hong, M., Sharma, S., Robertson, N. R., Mahajan, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00340-0 · Cited by 137 · see citing works

GIP mediates the incretin effect and glucose tolerance by dual actions on α cells and β cells

El, K., Gray, S. M., Capozzi, M. E., Knuth, E. R., Jin, E., Svendsen, B., Clifford, A., Brown, J. L., Encisco, S. E., Chazotte, B. M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abf1948 · Cited by 132 · see citing works

Effect of porcine gastric inhibitory polypeptide on β-cell function in type I and type II diabetes mellitus

Krarup, T., Saurbrey, N., Moody, A. J., Kühl, C., & Madsbad, S. (1987) · Metabolism · doi:10.1016/0026-0495(87)90153-3 · Cited by 128 · see citing works

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials

Hu, W., Song, R., Cheng, R., Liu, C., Guo, R., Tang, W., Zhang, J., Zhao, Q., Li, X., & Liu, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927859 · Cited by 127 · see citing works

Tanycytes control hypothalamic liraglutide uptake and its anti-obesity actions

Imbernon, M., Saponaro, C., Helms, H. C. C., Duquenne, M., Fernandois, D., Deligia, E., Denis, R. G. P., Chao, D. H. M., Rasika, S., Staels, B., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.06.002 · Cited by 124 · see citing works

Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.

Raufman, J., Singh, L., Singh, G., & Eng, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)36628-1 · Cited by 122 · see citing works

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170183 · Cited by 121 · see citing works

Glucagon-Like-Peptide-1 Receptor Expression in Normal and Diseased Human Thyroid and Pancreas

Waser, B., Blank, A., Karamitopoulou, E., Perren, A., & Reubi, J. C. (2015) · Modern Pathology · doi:10.1038/modpathol.2014.113 · Cited by 119 · see citing works

Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.

Patzelt, C., & Schiltz, E. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.16.5007 · Cited by 118 · see citing works

Gut glucagon, enteroglucagon, gut glucagonlike immunoreactivity, glicentin—Current status

Holst, J. J. (1983) · Gastroenterology · doi:10.1016/0016-5085(83)90388-8 · Cited by 117 · see citing works

The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice

Baggio, L. L., Ussher, J. R., McLean, B. A., Cao, X., Kabir, M. G., Mulvihill, E. E., Mighiu, A. S., Zhang, H., Ludwig, A., Seeley, R. J., et al. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.08.010 · Cited by 117 · see citing works

Oxyntomodulin (glicentin-(33–69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs

Baldissera, F. G. A., Holst, J. J., Knuhtsen, S., Hilsted, L., & Nielsen, O. V. (1988) · Regulatory Peptides · doi:10.1016/0167-0115(88)90099-7 · Cited by 114 · see citing works

The gut microbiota regulates hypothalamic inflammation and leptin sensitivity in Western diet-fed mice via a GLP-1R-dependent mechanism

Heiss, C. N., Mannerås-Holm, L., Lee, Y. S., Serrano-Lobo, J., Håkansson Gladh, A., Seeley, R. J., Drucker, D. J., Bäckhed, F., & Olofsson, L. E. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109163 · Cited by 114 · see citing works

Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8

Nauck, M. A., Schmidt, W. E., Ebert, R., STRIETZEL, J., Cantor, P., HOFFMANN, G. E., & Creutzfeldt, W. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-69-3-654 · Cited by 108 · see citing works

Glucagon‐like peptide‐2 inhibits antral emptying in man, but is not as potent as glucagon‐like peptide‐1

Nagell, C. F., Wettergren, A., Pedersen, J. F., Mortensen, D., & Holst, J. J. (2004) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520410004424 · Cited by 108 · see citing works

Distinct Neural Sites of GLP-1R Expression Mediate Physiological versus Pharmacological Control of Incretin Action

Varin, E. M., Mulvihill, E. E., Baggio, L. L., Koehler, J. A., Cao, X., Seeley, R. J., & Drucker, D. J. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.055 · Cited by 104 · see citing works

Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction

Ussher, J. R., Campbell, J. E., Mulvihill, E. E., Baggio, L. L., Bates, H. E., McLean, B. A., Gopal, K., Capozzi, M. E., Yusta, B., Cao, X., et al. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.003 · Cited by 103 · see citing works

Successful weight loss maintenance includes long-term increased meal responses of GLP-1 and PYY3-36

Iepsen, E. W., Lundgren, J., Holst, J. J., Madsbad, S., & Torekov, S. S. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-1116 · Cited by 101 · see citing works

Relationship of glicentin to proglucagon and glucagon in the porcine pancreas

Moody, A. J., Holst, J. J., Thim, L., & Jensen, S. L. (1981) · Nature · doi:10.1038/289514a0 · Cited by 100 · see citing works

GLP-1 secretion is regulated by IL-6 signalling: a randomised, placebo-controlled study

Ellingsgaard, H., Seelig, E., Timper, K., Coslovsky, M., Soederlund, L., Lyngbæk, M. P. P., Albrechtsen, N. J. W., Schmidt‐Trucksäss, A., Hanssen, H., Frey, W. O., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-05045-y · Cited by 96 · see citing works

GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: A randomised trial

Gögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95 · see citing works

Influence of Gastric Inhibitory Polypeptide Antiserum on Glucose-Induced Insulin Secretion in Rats

Ebert, R., & Creutzfeldt, W. (1982) · Endocrinology · doi:10.1210/endo-111-5-1601 · Cited by 93 · see citing works

Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6

Strain, W. D., Frenkel, O., James, M. A., Leiter, L. A., Rasmussen, S., Rothwell, P. M., Sejersten Ripa, M., Truelsen, T. C., & Husain, M. (2022) · Stroke · doi:10.1161/strokeaha.121.037775 · Cited by 93 · see citing works

Long-Acting Glucose-Dependent Insulinotropic Polypeptide Ameliorates Obesity-Induced Adipose Tissue Inflammation

Varol, C., Zvibel, I., Spektor, L., Mantelmacher, F. D., Vugman, M., Thurm, T., Khatib, M., Elmaliah, E., Halpern, Z., & Fishman, S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1401149 · Cited by 89 · see citing works

Glucagon‐like peptide‐1 receptor agonist inhibits aeroallergen‐induced activation of ILC2 and neutrophilic airway inflammation in obese mice

Toki, S., Newcomb, D. C., Printz, R. L., Cahill, K. N., Boyd, K. L., Niswender, K. D., & Peebles, R. S. (2021) · Allergy · doi:10.1111/all.14879 · Cited by 89 · see citing works

Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type <scp>2</scp> diabetes

Dahl, K., Brooks, A., Almazedi, F., Hoff, S. T., Boschini, C., & Bækdal, T. A. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14373 · Cited by 87 · see citing works

Loss of KDM1A in GIP-dependent primary bilateral macronodular adrenal hyperplasia with Cushing's syndrome: a multicentre, retrospective, cohort study

Chasseloup, F., Bourdeau, I., Tabarin, A., Regazzo, D., Dumontet, C., Ladurelle, N., Tosca, L., Amazit, L., Proust, A., Scharfmann, R., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00236-9 · Cited by 86 · see citing works

Gs/Gq signaling switch in β cells defines incretin effectiveness in diabetes.

Oduori, O. S., Murao, N., Shimomura, K., Takahashi, H., Zhang, Q., Dou, H.-Q., Sakai, S., Minami, K., Chanclón, B., Guida, C., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci140046 · Cited by 85 · see citing works

Differential importance of endothelial and hematopoietic cell GLP-1Rs for cardiometabolic versus hepatic actions of semaglutide

McLean, B. A., Wong, C. K., Kaur, K. D., Seeley, R. J., & Drucker, D. J. (2021) · JCI Insight · doi:10.1172/jci.insight.153732 · Cited by 84 · see citing works

Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice

Chen, S., Okahara, F., Osaki, N., & Shimotoyodome, A. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00418.2014 · Cited by 82 · see citing works

Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction

McLean, B. A., Wong, C. K., Kabir, M. G., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101641 · Cited by 82 · cited 3× · see citing works

GIP(3–30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release

Sparre‐Ulrich, A. H., Gabe, M. N., Gasbjerg, L. S., Christiansen, C. B., Svendsen, B., Hartmann, B., Holst, J. J., & ROSENKILDE, M. M. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.02.012 · Cited by 81 · see citing works

Incretin Effect After Oral Amino Acid Ingestion in Humans

Lindgren, O., Pacini, G., Tura, A., Holst, J. J., Deacon, C. F., & Åhrén, B. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3865 · Cited by 77 · see citing works

Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man

Lauritsen, K. B., Moody, A. J., Christensen, K. C., & Lindkár Jensen, S. (1980) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528009181538 · Cited by 77 · see citing works

Cardioprotective GLP-1 metabolite prevents ischemic cardiac injury by inhibiting mitochondrial trifunctional protein-α

Siraj, M. A., Mundil, D., Beca, S., Momen, A., Shikatani, E. A., Afroze, T., Sun, X., Liu, Y., Ghaffari, S., Lee, W. L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci99934 · Cited by 77 · see citing works

Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases

Wang, J., & Kim, C. H. (2022) · Endocrine Research · doi:10.1080/07435800.2021.1955255 · Cited by 74 · see citing works

Pancreatic pre-proglucagons are encoded by two separate mRNAs

Lund, P. K., Goodman, R. H., & Habener, J. F. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)69015-0 · Cited by 70 · see citing works

GIP regulates inflammation and body weight by restraining myeloid-cell-derived S100A8/A9

Mantelmacher, F. D., Zvibel, I., Cohen, K., Epshtein, A., Pasmanik-Chor, M., Vogl, T., Kuperman, Y., Weiss, S., Drucker, D. J., Varol, C., et al. (2018) · Nature Metabolism · doi:10.1038/s42255-018-0001-z · Cited by 70 · see citing works

Glucagon-Like Peptide-1 Receptor Agonism Improves Nephrotoxic Serum Nephritis by Inhibiting T-Cell Proliferation

Moschovaki Filippidou, F., Kirsch, A. H., Thelen, M., Kétszeri, M., Artinger, K., Aringer, I., Schabhüttl, C., Mooslechner, A. A., Frauscher, B., Pollheimer, M., et al. (2020) · The American Journal of Pathology · doi:10.1016/j.ajpath.2019.10.008 · Cited by 66 · see citing works

GLP-1 Levels Predict Mortality in Patients with Critical Illness as Well as End-Stage Renal Disease

Lebherz, C., Schlieper, G., Möllmann, J., Kahles, F., Schwarz, M., Brünsing, J., Dimkovic, N., Koch, A., Trautwein, C., Flöge, J., et al. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.03.010 · Cited by 65 · see citing works

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62 · see citing works

Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: potential therapeutic benefits in diabetic patients

Pugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61 · see citing works

Amino acids differ in their capacity to stimulate GLP-1 release from the perfused rat small intestine and stimulate secretion by different sensing mechanisms

Modvig, I. M., Kuhre, R. E., Jepsen, S. L., Xu, S. F. S., Engelstoft, M. S., Egerod, K. L., Schwartz, T. W., Ørskov, C., ROSENKILDE, M. M., & Holst, J. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00026.2021 · Cited by 58 · see citing works

Contributions A L'Étude des Variations Physiologiques De La Sécrétion Interne Du Pancréas

Zunz, E., & Barre, J. L. (1929) · Archives Internationales de Physiologie · doi:10.3109/13813452909145169 · Cited by 55 · see citing works

A Novel Human-Based Receptor Antagonist of Sustained Action Reveals Body Weight Control by Endogenous GLP-1

Patterson, J. T., Ottaway, N., Gelfanov, V. M., Smiley, D. L., Pérez–Tilve, D., Pfluger, P. T., Tschöp, M. H., & DiMarchi, R. D. (2010) · ACS Chemical Biology · doi:10.1021/cb1002015 · Cited by 53 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Receptors in Most Gastroenteropancreatic and Bronchial Neuroendocrine Tumors

Waser, B., Rehmann, R., Sanchez, C., Fourmy, D., & Reubi, J. C. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2454 · Cited by 53 · see citing works

Effect of Liraglutide on Arterial Inflammation Assessed as [ 18 F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Díaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. R., & Kjær, A. (2021) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.120.012174 · Cited by 53 · see citing works

Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models

Hiromura, M., Mori, Y., Kohashi, K., Terasaki, M., Shinmura, K., Negoro, T., Kawashima, H., Kogure, M., Wachi, T., Watanabe, R., et al. (2016) · Circulation Journal · doi:10.1253/circj.cj-16-0152 · Cited by 52 · see citing works

Cardiorenal mechanisms of action of glucagon-like-peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors

Cherney, D. Z. I., Udell, J. A., & Drucker, D. J. (2021) · Med · doi:10.1016/j.medj.2021.10.004 · Cited by 52 · see citing works

Liraglutide Reduces Both Atherosclerosis and Kidney Inflammation in Moderately Uremic LDLr-/- Mice

Bisgaard, L. S., Bosteen, M. H., Fink, L. N., Sørensen, C. M., Rosendahl, A., Mogensen, C., Rasmussen, S. E., Rolin, B. C., Nielsen, L. B., & Pedersen, T. X. (2016) · PLoS ONE · doi:10.1371/journal.pone.0168396 · Cited by 47 · see citing works

Glucagon, a second pancreatic hormone.

Foà, P. P., Galansino, G., & Pozza, G. (1957) · PubMed · Cited by 44 · see citing works

Glucagon-like peptide 1 levels predict cardiovascular risk in patients with acute myocardial infarction

Kahles, F., Rückbeil, M. V., Mertens, R. W., Foldenauer, A. C., Arrivas, M. C., Moellmann, J., Lebherz, C., Biener, M., Giannitsis, E., Katus, H. A., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz728 · Cited by 44 · see citing works

The diffuse endocrine-paracrine system of the gut in health and disease: ultrastructural features.

Solcia, E., Capella, C., Buffa, R., Usellini, L., Fiocca, R., Frigerio, B., Tenti, P., & Sessa, F. (1981) · PubMed · Cited by 41 · see citing works

Glucagon-Like Peptide-1 Receptor Regulates Thromboxane-Induced Human Platelet Activation

Cahill, K. N., Amin, T., Boutaud, O. G., Printz, R. L., Newcomb, D. C., Foer, D., Hodson, D. J., Broichhagen, J., Beckman, J. A., Yu, C., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.04.004 · Cited by 41 · see citing works

Glucagon Precursors Identified by Immunoprecipitation of Products of Cell-free Translation of Messenger RNA

Lund, P. K., Goodman, R. H., Jacobs, J., & Habener, J. F. (1980) · Diabetes · doi:10.2337/diab.29.7.583 · Cited by 40 · see citing works

Reagents and models for detecting endogenous GLP1R and GIPR

Ast, J., Broichhagen, J., & Hodson, D. J. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103739 · Cited by 40 · see citing works

Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?

Daousi, C., Pinkney, J. H., Cleator, J., Wilding, J. P. H., & Ranganath, L. R. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.03.004 · Cited by 38 · see citing works

Postprandial levels of GLP-1, GIP and glucagon after 2 years of weight loss with a Paleolithic diet: a randomised controlled trial in healthy obese women

Otten, J., Ryberg, M., Mellberg, C., Andersson, T., Chorell, E., Lindahl, B., Larsson, C. L., Holst, J. J., & Olsson, T. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0082 · Cited by 36 · see citing works

The gut hormone receptor GIPR links energy availability to the control of hematopoiesis

Pujadas, G., Varin, E. M., Baggio, L. L., Mulvihill, E. E., Bang, K. W. A., Koehler, J. A., Matthews, D., & Drucker, D. J. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101008 · Cited by 35 · see citing works

Genetic disruption of the Gipr in Apoe−/− mice promotes atherosclerosis

Pujadas, G., Baggio, L. L., Kaur, K. D., McLean, B. A., Cao, X., & Drucker, D. J. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101586 · Cited by 34 · see citing works

GIP Affects Hepatic Fat and Brown Adipose Tissue Thermogenesis but Not White Adipose Tissue Transcriptome in Type 1 Diabetes

Heimbürger, S. M. N., Hoe, B., Nielsen, C. N., Bergmann, N. C., Skov‐Jeppesen, K., Hartmann, B., Holst, J. J., Dela, F., Overgaard, A. J., Størling, J., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac542 · Cited by 32 · see citing works

GLP-1 Receptor Signaling Differentially Modifies the Outcomes of Sterile vs Viral Pulmonary Inflammation in Male Mice

Sato, T., Shimizu, T., Fujita, H., Imai, Y., Drucker, D. J., Seino, Y., & Yamada, Y. (2020) · Endocrinology · doi:10.1210/endocr/bqaa201 · Cited by 29 · see citing works

GLP-2 receptors in human disease: High expression in gastrointestinal stromal tumors and Crohn’s disease

Körner, M., Rehmann, R., & Reubi, J. C. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.08.008 · Cited by 27 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Receptor Deficiency Leads to Impaired Bone Marrow Hematopoiesis

Mantelmacher, F. D., Fishman, S., Cohen, K., Pasmanik Chor, M., Yamada, Y., Zvibel, I., & Varol, C. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601441 · Cited by 27 · see citing works

Secretory effects of gastric inhibitory polypeptide on the isolated perfused porcine pancreas

Jensen, S. L., Holst, J. J., Nielsen, O. V., & Lauritsen, K. B. (1981) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1981.tb06731.x · Cited by 17 · see citing works

A pilot clinical study to Evaluate Liraglutide-mediated Anti-platelet activity in patients with type-2 Diabetes (ELAID study)

Loganathan, J., Cohen, A. C., Kaloupis, G. M., Harris, C., Chronopoulos, A., James, V., Hamilton, J. R., Green, S., Wallis, A., Morgan, S. J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108188 · Cited by 17 · see citing works

Evidence for Relationship Between Early Dumping and Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Øhrstrøm, C. C., Worm, D., Kielgast, U. L., Holst, J. J., & Hansen, D. L. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04387-6 · Cited by 16 · see citing works

Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry

Hale, P. M., Ali, A. K., Buse, J. B., McCullen, M. K., Ross, D. S., Sabol, M. E., Tuttle, R. M., & Stemhagen, A. (2020) · Thyroid · doi:10.1089/thy.2019.0591 · Cited by 14 · see citing works

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans

Modrzynska, J., Klein, C. F., Iversen, K. K., Bundgaard, H., Hartmann, B., Mose, M., Rittig, N. F., Møller, N., Holst, J. J., & Albrechtsen, N. J. W. (2021) · Endocrine Connections · doi:10.1530/ec-20-0590 · Cited by 10 · see citing works

Glucose- and Bile Acid-Stimulated Secretion of Gut Hormones in the Isolated Perfused Intestine Is Not Impaired in Diet-Induced Obese Mice

Hunt, J. E., Holst, J. J., & Jepsen, S. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.884501 · Cited by 10 · see citing works

Weight loss did not modify macronutrient specific response of hormones and satiety in overweight and obese people without metabolic disease – results from a clinical trial

Li, L., Decker, A.-M., Stobäus, N., Beer, F., Grittner, U., Spranger, J., & Mai, K. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.02.004 · Cited by 3 · see citing works

Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity

Drucker, D. J. (2024) · Diabetes Care · doi:10.2337/dci24-0003 · Cited by 383 · see citing works

Diabetes mellitus—Progress and opportunities in the evolving epidemic

Abel, E. D., Gloyn, A. L., Evans‐Molina, C., Joseph, J. J., Misra, S., Pajvani, U. B., Simcox, J., Suszták, K., & Drucker, D. J. (2024) · Cell · doi:10.1016/j.cell.2024.06.029 · Cited by 330 · see citing works

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Apperloo, E. M., Neuen, B. L., Fletcher, R. A., Jongs, N., Anker, S. D., Bhatt, D. L., Butler, J., Cherney, D. Z. I., Herrington, W. G., Inzucchi, S. E., et al. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00155-4 · Cited by 177 · see citing works

Type 2 Diabetes Mellitus: A Comprehensive Review of Pathophysiology, Comorbidities, and Emerging Therapies

Singh, A. P., Shadangi, S., Gupta, P. K., & Rana, S. (2025) · Comprehensive physiology · doi:10.1002/cph4.70003 · Cited by 183 · see citing works

The benefits of GLP-1 drugs beyond obesity

Drucker, D. J. (2024) · Science · doi:10.1126/science.adn4128 · Cited by 169 · see citing works

GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

Campbell, J. E., Müller, T. D., Finan, B., DiMarchi, R. D., Tschöp, M. H., & D’Alessio, D. A. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.010 · Cited by 149 · see citing works

GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management

Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125 · see citing works

A comprehensive spatio-cellular map of the human hypothalamus

Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2025) · Nature · doi:10.1038/s41586-024-08504-8 · Cited by 105 · see citing works

The penetration of therapeutics across the blood-brain barrier: Classic case studies and clinical implications

Banks, W. A., Rhea, E. M., Reed, M. J., & Erickson, M. A. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101760 · Cited by 90 · see citing works

Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node

Lubberding, A. F., Veedfald, S., Achter, J. S., Nissen, S. D., Soattin, L., Sorrentino, A., Torres-Vega, E., Linz, B. M., Eggertsen, C. E., Mulvey, J. F., et al. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae120 · Cited by 86 · see citing works

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 68 · see citing works

Obesity, diabetes, and inflammation: Pathophysiology and clinical implications

Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 64 · see citing works

The expanding landscape of GLP-1 medicines

Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 70 · see citing works

GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms

Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024) · Journal of Endocrinology · doi:10.1530/joe-24-0046 · Cited by 51 · see citing works

Targeting organ-specific mitochondrial dysfunction to improve biological aging

Madreiter‐Sokolowski, C. T., Hiden, U., Krstić, J., Panzitt, K., Wagner, M., Enzinger, C., Khalil, M., Abdellatif, M., Malle, E., Madl, T., et al. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108710 · Cited by 54 · see citing works

The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice

Forny Germano, L., Koehler, J. A., Baggio, L. L., Cui, F., Wong, C. K., Rittig, N., Cao, X., Matthews, D., & Drucker, D. J. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102019 · Cited by 50 · see citing works

Renal effects of GLP-1 receptor agonists and tirzepatide in individuals with type 2 diabetes: seeds of a promising future

Caruso, I., & Giorgino, F. (2024) · Endocrine · doi:10.1007/s12020-024-03757-9 · Cited by 54 · see citing works

Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Obstructive Sleep Apnea Syndrome Management: A Narrative Review

Dragonieri, S., Portacci, A., Quaranta, V. N., Carratù, P., Lázár, Z., Carpagnano, G. E., & Bikov, A. (2024) · Diseases · doi:10.3390/diseases12090224 · Cited by 45 · see citing works

Hypoxia signaling in the adipose tissue

Huynh, P. M., Wang, F., & An, Y. (2024) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjae039 · Cited by 37 · see citing works

GLP-1 receptor agonists, are we witnessing the emergence of a paradigm shift for neuro-cardio-metabolic disorders?

Arredouani, A. (2025) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36 · see citing works

The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors

Gonzalez-Rellan, M. J., Riobello, C., Fang, S., da Silva, E. M., Koehler, J. A., Shang, R., Hammoud, R., Cao, X., Varela‐Rey, M., & Drucker, D. J. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.03.011 · Cited by 33 · see citing works

Growth hormone-releasing hormone and its analogues in health and disease

Granata, R., Leone, S., Zhang, X., Gesmundo, I., Steenblock, C., Cai, R., Sha, W., Ghigo, E., Hare, J. M., Bornstein, S. R., et al. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01052-1 · Cited by 31 · see citing works

Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Solini, A., Tricò, D., & Del Prato, S. (2023) · Diabetologia · doi:10.1007/s00125-023-05973-w · Cited by 32 · see citing works

Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1/leptin dual agonist

Polex-Wolf, J., Deibler, K., Hogendorf, W. F. J., Bau, S. S., Glendorf, T., Stidsen, C. E., Tornøe, C. W., Dong, T., Lundh, S. H., Pyke, C., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk4908 · Cited by 29 · see citing works

Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions

Karacabeyli, D., & Lacaille, D. V. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01302-0 · Cited by 28 · see citing works

Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity

Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 26 · see citing works

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Bailey, C. J., Flatt, P. R., & Conlon, J. M. (2024) · Peptides · doi:10.1016/j.peptides.2024.171149 · Cited by 25 · see citing works

Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database

Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., & Wu, X. (2024) · Endocrine · doi:10.1007/s12020-024-04112-8 · Cited by 25 · see citing works

Considering the use of GLP-1 receptor agonists in women with obesity prior to pregnancy: a narrative review

Price, S., & Nankervis, A. J. (2025) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-024-07849-9 · Cited by 24 · see citing works

Retatrutide—A Game Changer in Obesity Pharmacotherapy

Katsi, V., Koutsopoulos, G., Fragoulis, C., Dimitriadis, K., & Tsioufis, K. (2025) · Biomolecules · doi:10.3390/biom15060796 · Cited by 29 · see citing works

Emerging incretin- and multi-agonist-based treatments – the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond

Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 24 · see citing works

Glucose-dependent insulinotropic polypeptide receptor signaling alleviates gut inflammation in mice

Hammoud, R., Kaur, K. D., Koehler, J. A., Baggio, L. L., Wong, C. K., Advani, K. E., Yusta, B., Efimova, I., Gribble, F. M., Reimann, F., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.174825 · Cited by 24 · see citing works

Attenuating mitochondrial dysfunction and morphological disruption with PT320 delays dopamine degeneration in MitoPark mice

Wang, V., Tseng, K.-Y., Kuo, T., Huang, E. Y., Lan, K.-L., Chen, Z., Ma, K., Greig, N. H., Jung, Y. J., Choi, H.-I., et al. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01025-6 · Cited by 22 · see citing works

Incretin-based therapeutics for the treatment of neurodegenerative diseases

Vear, A., Heneka, M. T., & Clemmensen, C. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01263-4 · Cited by 20 · see citing works

Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System

Chen, H., Liu, S., Gao, S. H., Shi, H., Yan, Y., Xu, Y., Fang, J., Wang, W., Chen, H., & Liu, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-01206-9 · Cited by 19 · see citing works

Glucose-Dependent Insulinotropic Polypeptide Inhibits AGE-Induced NADPH Oxidase-Derived Oxidative Stress Generation and Foam Cell Formation in Macrophages Partly via AMPK Activation

Terasaki, M., Yashima, H., Mori, Y., Saito, T., Inoue, N., Matsui, T., Osaka, N., Fujikawa, T., Ohara, M., & Yamagishi, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179724 · Cited by 18 · see citing works

Single‐cell transcriptomics of human organoid‐derived enteroendocrine cell populations from the small intestine

Smith, C. A., Lu, V. B., Bakar, R. B., Miedzybrodzka, E. L., Davison, A., Goldspink, D. A., Reimann, F. M., & Gribble, F. M. (2024) · The Journal of Physiology · doi:10.1113/jp287463 · Cited by 18 · see citing works

Proglucagon-derived peptides: human physiology and therapeutic potential

Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 18 · see citing works

The Co-occurrence of Depression and Obesity

McIntyre, R. S. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.24com15322 · Cited by 17 · see citing works

New drug therapies for metabolic dysfunction-associated steatohepatitis

Chiang, J. Y. L. (2025) · Liver Research · doi:10.1016/j.livres.2025.01.001 · Cited by 16 · see citing works

Unveiling the Therapeutic Potential of the Second-Generation Incretin Analogs Semaglutide and Tirzepatide in Type 1 Diabetes and Latent Autoimmune Diabetes in Adults

Infante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 16 · see citing works

Exendin-4 improves cerebral ischemia by relaxing microvessels, rapidly increasing cerebral blood flow after reperfusion

Chen, Y., Wang, L., Zhou, Y., Wang, Y., Qin, W., Wang, M., Liu, B., Tian, Q., Xu, H., Shen, H., et al. (2025) · Basic Research in Cardiology · doi:10.1007/s00395-025-01096-y · Cited by 17 · see citing works

Low‐calorie, high‐protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity

Rodrigo‐Carbó, C., Madinaveitia‐Nisarre, L., Pérez‐Calahorra, S., Gracia‐Rubio, I., Cebollada, A., Galindo‐Lalana, C., Mateo‐Gállego, R., & Lamíquiz-Moneo, I. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16013 · Cited by 16 · see citing works

GLP-1 and ghrelin inversely regulate insulin secretion and action in pancreatic islets, vagal afferents, and hypothalamus for controlling glycemia and feeding

Yada, T., Dezaki, K., & Iwasaki, Y. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00168.2025 · Cited by 16 · see citing works

Beyond Weight Loss: the Emerging Role of Incretin-Based Treatments in Cardiometabolic HFpEF

Capone, F., Nambiar, N., & Schiattarella, G. G. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001117 · Cited by 15 · see citing works

Incretin and glucagon receptor polypharmacology in chronic kidney disease

McFarlin, B. E., Duffin, K. L., & Konkar, A. A. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00374.2023 · Cited by 15 · see citing works

Incretin mimetics and acute pancreatitis: enemy or innocent bystander?

Pratley, R. E., Saeed, Z. I., & Casu, A. (2024) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001057 · Cited by 14 · see citing works

Towards Improved Bioavailability of Cereal Inositol Phosphates, Myo-Inositol and Phenolic Acids

Żyła, K., & Duda‐Chodak, A. (2025) · Molecules · doi:10.3390/molecules30030652 · Cited by 15 · see citing works

Glucagon-like peptide-1 receptor modulates cerebrospinal fluid secretion and intracranial pressure in rats

Jensen, M. N., Israelsen, I. M. E., Wardman, J. H., Jensen, D. B., Andersen, D. B., Toft‐Bertelsen, T. L., Rath, M. F., Holst, J. J., ROSENKILDE, M. M., & MacAulay, N. (2025) · Fluids and Barriers of the CNS · doi:10.1186/s12987-025-00652-x · Cited by 15 · see citing works

Repurposing glucagon-like peptide-1 receptor agonists for the treatment of neurodegenerative disorders

Sabbagh, M. N., Cummings, J. L., Ballard, C. G., van der Flier, W. M., Heneka, M. T., Holst, J. J., Knudsen, L. B., Salloway, S., Tansey, M. G., & Drucker, D. J. (2025) · Nature Aging · doi:10.1038/s43587-025-01029-3 · Cited by 14 · see citing works

GLP-1 receptor agonists and next-generation metabolic hormone therapies in chronic kidney disease

Alicic, R. Z., Neumiller, J. J., & Tuttle, K. R. (2026) · Nature Reviews Nephrology · doi:10.1038/s41581-025-01036-y · Cited by 17 · see citing works

Weight Loss Interventions for Adults With Obesity-Related Asthma

Foer, D., Forno, E., Holguín, F., & Cahill, K. N. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.12.041 · Cited by 14 · see citing works

Incretins and the cardiovascular system: bridging digestion with metabolism

Avogaro, A., & Fadini, G. P. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00166-4 · Cited by 15 · see citing works

Colonic L-cell impairment in aged subjects with type 2 diabetes leads to diminished GLP-1 production

Wang, Q., Zhang, W., Zhao, Y., Chen, H.-L., Liu, Q., Wang, Z., Zeng, L.-T., Li, J., Chen, S., Wei, L., et al. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102907 · Cited by 13 · see citing works

G protein-coupled receptors and obesity

Pocai, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1301017 · Cited by 14 · see citing works

G protein-coupled receptors driven intestinal glucagon-like peptide-1 reprogramming for obesity: Hope or hype?

Patil, M., Casari, I., Warne, L. N., & Falasca, M. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116245 · Cited by 13 · see citing works

Advances in small-molecule insulin secretagogues for diabetes treatment

Su, J., Xu, J., Hu, S., Ye, H., Xie, L. N., & Ouyang, S. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117179 · Cited by 13 · see citing works

Fish-hunting cone snail disrupts prey’s glucose homeostasis with weaponized mimetics of somatostatin and insulin

Yeung, H. Y., Ramiro, I. B. L., Andersen, D. B., Koch, T. L., Hamilton, A., Bjørn-Yoshimoto, W. E., Espino, S. S., Vakhrushev, S. Y., Pedersen, K. B., de Haan, N., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50470-2 · Cited by 13 · see citing works

Translating physiology of the arterial chemoreflex into novel therapeutic interventions targeting carotid bodies in cardiometabolic disorders

Żera, T., Paleczny, B., Siński, M., Conde, S. V., Narkiewicz, K., Ponikowski, P. P., Paton, J. F. R., & Niewiński, P. (2025) · The Journal of Physiology · doi:10.1113/jp285081 · Cited by 14 · see citing works

Incretin Hormones: Mechanisms, Therapeutic Implications, and Future Directions in Glucose Regulation and Diabetes Management

Zargar, A. A., Mehta, V., Huddar, V., Gupta, R., Bhandari, K., Posa, M. K., Ramya, T. S., Snigdha, D., Vijayakumar, B., Sharma, M. C., et al. (2025) · Current Proteomics · doi:10.1016/j.curpro.2025.100014 · Cited by 12 · see citing works

Potent and Protease Resistant Azapeptide Agonists of the GLP‐1 and GIP Receptors

Dinsmore, T. C., Liu, J., Miao, J., Ünsal, Ö., Sürmeli, D., Beinborn, M., Lin, Y., & Kumar, K. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202410237 · Cited by 12 · see citing works

Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus

He, X., Zhao, W., Li, P., Zhang, Y., Li, G., Su, H., Lu, B., & Pang, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1483792 · Cited by 16 · see citing works

Glucagon-like peptide-1 medicines and cancer

Yabut, J. M., & Drucker, D. J. (2026) · Nature Cancer · doi:10.1038/s43018-025-01110-1 · Cited by 11 · see citing works

Gut‐derived appetite hormones do not explain energy intake differences in humans following low‐carbohydrate versus low‐fat diets

Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2024) · Obesity · doi:10.1002/oby.24104 · Cited by 11 · see citing works

Cardioprotective benefits of metabolic surgery and GLP-1 receptor agonist–based therapies

Morissette, A., & Mulvihill, E. E. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.07.012 · Cited by 11 · see citing works

Regulation of GLP-1 and Glucagon Receptor Function by β-Arrestins in Metabolically Important Cell Types

Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 11 · see citing works

Pharmacogenomics of Tirzepatide: Genomic Insights into Dual GIP/GLP-1 Agonist Response in Type 2 Diabetes and Atherosclerosis

Song, Z., Tang, Y., Peng, M., Han, R., & He, P. (2025) · Pharmaceuticals · doi:10.3390/ph18091261 · Cited by 11 · see citing works

Repurposing incretin therapies: a narrative review of emerging indications across cardiometabolic, liver, kidney, neurological, psychiatric, and other systems

Alhomoud, I. S., Wheeler, S. E., & Dixon, D. L. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0038 · Cited by 11 · see citing works

Amino acids contribute to adaptive thermogenesis. New insights into the mechanisms of action of recent drugs for metabolic disorders are emerging.

Ruocco, C., Malavazos, A., Ragni, M., Carruba, M., Valerio, A., Iacobellis, G., & Nisoli, E. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106892 · Cited by 9 · see citing works

The Therapeutic Potential of Glucagon-like Peptide 1 Receptor Agonists in Traumatic Brain Injury

Harej, A., Pilipović, K., Belančić, A., Juretić, L., Vitezić, D., & Mršić‐Pelčić, J. (2024) · Pharmaceuticals · doi:10.3390/ph17101313 · Cited by 9 · see citing works

Effectiveness of glucagon-like peptide-1 receptor agonists for reduction of body mass index and blood glucose control in patients with type 2 diabetes mellitus and obesity: A retrospective cohort study and difference-in-difference analysis

Siriyotha, S., Anothaisintawee, T., Looareesuwan, P., Nimitphong, H., McKay, G. J., Attia, J., & Thakkinstian, A. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-086424 · Cited by 9 · see citing works

Molecular Interaction Between Vasopressin and Insulin in Regulation of Metabolism: Impact on Cardiovascular and Metabolic Diseases

Szczepanska‐Sadowska, E. K., Cudnoch‐Jędrzejewska, A., & Żera, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252413307 · Cited by 9 · see citing works

G Protein-Coupled Receptor 17 Inhibits Glucagon-like Peptide-1 Secretion via a Gi/o-Dependent Mechanism in Enteroendocrine Cells

Conley, J. M., Jochim, A., Evans‐Molina, C., Watts, V. J., & Ren, H. (2024) · Biomolecules · doi:10.3390/biom15010009 · Cited by 9 · see citing works

Innovative Molecules and Delivery Technologies Enabling the Future of GLP-1-based Therapies

Xu, Y., Drucker, D. J., Traverso, G., & Beloqui, A. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf027 · Cited by 9 · see citing works

Glucagon-like peptide-1 medicines in neurological and psychiatric disorders

Fang, S., Cui, F., & Drucker, D. J. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102511 · Cited by 9 · see citing works

Obesity management for the treatment of type 2 diabetes: emerging evidence and therapeutic approaches

Morissette, A., & Mulvihill, E. E. (2024) · Journal of Pharmacy &amp; Pharmaceutical Sciences · doi:10.3389/jpps.2024.13065 · Cited by 8 · see citing works

Glucokinase activators and imeglimin: new weaponry in the armamentarium against type 2 diabetes

Sjöholm, Å. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004291 · Cited by 8 · see citing works

Antinociceptive Behavior, Glutamine/Glutamate, and Neopterin in Early-Stage Streptozotocin-Induced Diabetic Neuropathy in Liraglutide-Treated Mice under a Standard or Enriched Environment

Andreeva-Gateva, P. A., Hristov, M., Ivanova, N. M., Vasileva, D., Ivanova, A., Sabit, Z., Bogdanov, T. G., Apostolova, S. N., & Tzoneva, R. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910786 · Cited by 8 · see citing works

Exploring neutrophils as therapeutic targets in cardiometabolic diseases

Albiero, M., & Baragetti, A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.12.003 · Cited by 9 · see citing works

Impact of Glucagon-like Peptide-1 Receptor Agonists on Mental Illness: Evidence from a Mendelian Randomization Study

Xiang, L., & Peng, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26062741 · Cited by 8 · see citing works

GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review

Gholami, M., Balajam, N. Z., Rakhsha, S. S., Sajjadi‐Jazi, S. M., Shafiee, G., & Heshmat, R. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01604-w · Cited by 9 · see citing works

Molecular mapping and functional validation of GLP-1R cholesterol binding sites in pancreatic beta cells

Oqua, A. I., Chao, K., Eid, L. E., Casteller, L., Baxter, B. P., Miguéns‐Gómez, A., Barg, S., Jones, B. J., de la Serna, J. B., Rouse, S. L., et al. (2025) · eLife · doi:10.7554/elife.101011.3 · Cited by 8 · see citing works

GLP-1 receptor agonists show no detrimental effect on sperm quality in mouse models and cell lines

Yin, D., Li, F., Li, X., Wei, T., Shan, C., Zhang, Z., & Wei, R. (2025) · Endocrine · doi:10.1007/s12020-025-04245-4 · Cited by 8 · see citing works

Molecular Design of Unimolecular Tetra-Receptor Agonists

Dinsmore, T. C., Cortigiano, J. E., Xiang, S., Spenciner, M. V., Dobbins, A. R., Zhao, R. R., Waldman, B. M., Beinborn, M., & Kumar, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c04095 · Cited by 8 · see citing works

Targeting Metabolic Dysregulation in Alzheimer’s Disease: A Potential Therapeutic Strategy

Barnwal, N., Dubey, S., & Tiwari, P. K. (2025) · Current Drug Metabolism · doi:10.2174/0113892002408089250912080734 · Cited by 8 · see citing works

Therapeutic efficacy of 4-hydroxyisoleucine in experimental rat model of demyelination: Neuroprotection through IGF-1 and GLP-1 level restoration

Khan, Z., Mehan, S., & Gupta, G. D. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.157448 · Cited by 8 · see citing works

Systematic Review: Efficacy, Safety and Metabolic Outcomes of GLP‐1 Receptor Agonists in Inflammatory Bowel Disease

Maracle, B., Quan, S., Hamilton, P., Shaikh, A., Hazra, D., Lorenzetti, D., Gold, S. L., Raman, M., & St‐Pierre, J. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70485 · Cited by 8 · see citing works

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease

Bernardini, F., Nusca, A., Coletti, F., Porta, Y. L., Piscione, M., Vespasiano, F., Mangiacapra, F., Ricottini, E., Melfi, R., Cavallari, I., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071858 · Cited by 8 · see citing works

Incretins Beyond the Pancreas: Exploring the Impact of GIP and GLP-1/2 on Bone Remodeling

Zhao, H., Sun, J., & Ren, Z. (2024) · Discovery Medicine · doi:10.24976/discov.med.202436183.62 · Cited by 9 · see citing works

Interrupting T-Cell Memory Ameliorates Exaggerated Metabolic Response to Weight Cycling

Garcia, J. N., Cottam, M. A., Rodriguez, A. S., Agha, A. F. H., Caslin, H. L., Winn, N. C., & Hasty, A. H. (2026) · Diabetes · doi:10.2337/db25-0605 · Cited by 8 · see citing works

An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review

Hasan, M. A., Schwartz, S. S., McKenna, V., & Ing, R. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06758-1 · Cited by 7 · see citing works

Human HYPOMAP: A comprehensive spatio-cellular map of the human hypothalamusPreprint

Tadross, J. A., Steuernagel, L., Dowsett, G. K. C., Kentistou, K. A., Lundh, S. H., Porniece, M., Klemm, P., Rainbow, K., Hvid, H., Kania, K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.09.15.557967 · Cited by 8 · see citing works

Effects of dulaglutide and trelagliptin on beta-cell function in patients with type 2 diabetes: a randomized controlled study: DUET-beta study

Kondo, Y., Satoh, S., & Terauchi, Y. (2024) · Diabetology International · doi:10.1007/s13340-024-00717-6 · Cited by 7 · see citing works

GHRH in diabetes and metabolism

Steenblock, C., & Bornstein, S. R. (2024) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-024-09930-9 · Cited by 7 · see citing works

Secretagogin Is Highly Expressed in Enteroendocrine K Cells and Plays a Critical Role in Nutrient-Induced GIP Secretion

Liu, X., Liu, X., Hu, Y., Wang, X., Yang, X., Bin, Y., Zhou, Y., Zhou, L., Fan, G., & Yang, J. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf022 · Cited by 7 · see citing works

Cardiovascular effects of anti-obesity medications: the perils and promise

Zheng, H. (2025) · Cardiology Plus · doi:10.1097/cp9.0000000000000114 · Cited by 7 · see citing works

Proinflammatory cytokine-induced alpha cell impairment in human islet microtissues is partially restored by dual incretin receptor agonism

Henriksen, K., Rufer, C., Title, A. C., Jawurek, S., Hartmann, B., Holst, J. J., Knop, F. K., Yesildag, B., & Størling, J. (2025) · Diabetologia · doi:10.1007/s00125-025-06425-3 · Cited by 7 · see citing works

Hormonal modulation, mitochondria and Alzheimer’s prevention: the role of GLP-1 agonists and estrogens

Lizcano, F., Sanabria, D., & Aviles, E. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1622186 · Cited by 8 · see citing works

Potential of non-digestible polysaccharides as GLP-1 secretagogues: action mechanisms, structure-activity relationships and clinical applications

Shang, Z.-Z., Ye, H.-Y., Li, Q.-M., Zha, X., & Luo, J. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124024 · Cited by 7 · see citing works

Novel cardiovascular metabolic risk factor mechanisms and therapeutic opportunities

Evans, P. C., Vilahur, G., Kleinbongard, P., Osto, E., Remme, C. A., Madonna, R., Aksentijević, D., Sourij, H., Davidson, S. M., Santovito, D., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag116 · Cited by 8 · see citing works

Pharmacology, physiology, and mechanisms of incretin hormone action.

Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · see citing works

Incretin actions beyond the pancreas: lessons from knockout mice

Yabe, D., & Seino, Y. (2013) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2013.09.013 · Cited by 53 · see citing works

Incretins

Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 58 · see citing works

Pleiotropic Actions of the Incretin Hormones

McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 40 · see citing works

Glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1: Incretin actions beyond the pancreas

Seino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247 · see citing works